FINWIRES · TerminalLIVE
FINWIRES

Steadfast Group Enters Takeover Deal With Amwins, Dragoneer, KKR-Backed Consortium

By

Steadfast Group (ASX:SDF) entered into a scheme implementation deed with Amwins Australasia, a subsidiary of Amwins Group, and Starboard BidCo, an entity backed by affiliates of Dragoneer Investment Group and Kohlberg Kravis Roberts (KKR), under which the bidder agreed to acquire all issued shares in the company for AU$6 per share in cash, less the cash amount of any permitted dividends of up to AU$0.20 per share, according to an Australian bourse filing on Aug. 21 after market hours.

The offer represents a nearly 52% premium to the company's undisturbed share price of AU$3.95, valuing the company at an enterprise value of around AU$7.7 billion, per the filing.

The company's board unanimously recommends the deal, which remains subject to shareholder, court and regulatory approvals, including clearance from the Foreign Investment Review Board, Australian Competition and Consumer Commission and other regulators, the filing said.

Amwins will acquire the company's underwriting agency business following completion of the deal, while Starboard BidCo will retain the broking business.

Implementation is expected to take place in December, and no action is required from shareholders at this stage, the filing added.

Related Articles

Asia

Zhongji Innolight's Attributable Profit, Revenue Surge in H1

Zhongji Innolight (HKG:3308, SHE:300308) reported 13.7 billion yuan in profit attributable to owners for the first half, compared with 4 billion yuan a year ago, a Friday bourse filing showed.EPS moved to 12.19 yuan from 3.60 yuan year over year.For the six months ended June 30, revenue was 41.8 billion yuan, versus 14.8 billion yuan previously, the optical interconnect service provider said.The company declared an interim dividend of 12 yuan per 10 shares. Dividends to holders of Hong Kong-listed shares of record as of Sept. 10 will be payable on Oct. 9.

HKG:3308SHE:300308
Asia

Henlius Biotech Posts Higher H1 Attributable Profit; Revenue Up

Shanghai Henlius Biotech (HKG:2696) reported 430.4 million yuan in profit attributable to equity holders of the parent for the first half, compared with 390.1 million yuan a year ago, a Friday bourse filing showed.EPS moved to 0.79 yuan from 0.72 yuan year over year.For the six months ended June 30, revenue was 3.59 billion yuan, versus 2.82 billion yuan, the biologics medicine company said.

HKG:2696
Asia

Yuexiu Transport Infrastructure Sees Toll Revenue Drop in Most Expressways in July

Toll revenue of a majority of Yuexiu Transport Infrastructure's (HKG:1052) expressways declined year on year for the month of July, mainly due to a decrease in toll traffic volume for most of the company-operated expressways during the reporting monthAmong the company's expressways, the GNSR Expressway posted the highest toll revenue of 83.3 million yuan with an average daily toll traffic volume of 309,225, a Friday Hong Kong bourse filing said. The expressway recorded a 6.5% year-on-year decline in toll traffic volume.Han'e Expressway recorded the biggest year-on-year decline in toll revenue, decreasing by 63% to 11.1 million yuan.

HKG:1052